VYNE Therapeutics Inc(VYNE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -26.68 | Insider Own | 19.55% | Shs Outstand | 0.9M | Perf Week | 25.33% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.7M | Perf Month | 55.35% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 30.73% | Short Float | 0.53% | Perf Quarter | 56.94% |
| Income | -0.02B | P/S | 54.56 | EPS this Y | - | Inst Trans | 13.74% | Short Ratio | 0.14 | Perf Half Y | 74.4% |
| Sales | 0.00B | P/B | 0.77 | EPS next 5Y | - | ROA | -52.78% | Short Interest | 0.00M | Perf YTD | 74.52% |
| Book/sh | 36.93 | P/C | 0.98 | EPS past 3/5Y | 62.06% 66.27% | ROE | -63.16% | 52W High | -36.53% ($44.99) | Perf Year | -30.66% |
| Cash/sh | 29 | P/FCF | - | Sales past 3/5Y | 6.12% -51.39% | ROIC | -87.09% | 52W Low | 260.93% ($7.91) | Perf 3Y | -73.07% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 46.11% | Gross Margin | 94.93% | Volatility(W/M) | 12.48% 7.48% | Perf 5Y | -97.92% |
| Dividend TTM | - | EV/Sales | -0.84 | Sales Y/Y TTM | -24.96% | Oper. Margin | -5367.62% | ATR (14) | 1.89 | Perf 10Y | - |
| Dividend Ex-Date | 2026/7/24 | Quick Ratio | 20.86 | EPS Q/Q | 58.47% | Profit Margin | -4726.21% | RSI (14) | 84.01 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 20.86 | Sales Q/Q | -57.43% | SMA20 | 34.57% ($21.22) | Beta | 1.95 | Target Price | $100 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | 45.01% ($19.7) | Rel Volume | 3.59 | Prev Close | $25.45 |
| Employees | 10 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 1.92% 35.2% | SMA200 | 78.5% ($16) | Avg Volume(3M) | 0.03M | Price | $28.56 |
| IPO | 2018/1/25 | Option/Short | No/Yes | Trades | 1851 | Volume | 93,800 | Change | 12.22% |
💊 VYNE Therapeutics () is a clinical-stage small biotech developing treatments for immune and inflammatory diseases based on its BET protein inhibitor (InhiBET™) platform. The company holds both oral and topical drug candidates targeting a range of indications, including psoriasis, vitiligo, and myelofibrosis. With no marketed flagship product yet, its corporate value is heavily dependent on the clinical outcomes of its pipeline.
Over the past 1 year, roughly in the middle
37% below its 1-year high.
Traded more than usual. That is 359% of its average volume.
VYNE has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $5,456. Peers typically go for $885.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.9%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 30.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #457 of 598 in the industry
Based on market cap of $25M.
ABVC#455 ABVC BioPharma Inc $26M PER - 
BYSI#456 BeyondSpring Inc $25M PER - VYNE#457 VYNE Therapeutics Inc $25M PER - 
BSEM#457 BioStem Technologies Inc $24M PER - 
RNAZ#458 TransCode Therapeutics Inc $24M PER - 
FAQ
What kind of company is VYNE?
VYNE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VYNE?
The market cap of VYNE is approximately $25M, ranking 5,196 within its sector.
What is the 52-week high and low for VYNE?
VYNE has recorded a 52-week high of $44.99 and a low of $7.91.
